Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase by Hutchinson, Jonathan P et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structural and mechanistic basis of differentiated inhibitors of
the acute pancreatitis target kynurenine-3-monooxygenase
Citation for published version:
Hutchinson, JP, Rowland, P, Taylor, MRD, Christodoulou, EM, Haslam, C, Hobbs, CM, Holmes, D, Liddle,
J, Mole, D, Uings, IJ, Walker, AL, Webster, S, Mowat, C & Chung, C 2017, 'Structural and mechanistic basis
of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase', Nature
Communications. https://doi.org/10.1038/ncomms15827
Digital Object Identifier (DOI):
10.1038/ncomms15827
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Nature Communications
Publisher Rights Statement:
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use,
sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this article are included in the article’s Creative
Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
ARTICLE
Received 7 Jan 2017 | Accepted 28 Apr 2017 | Published 12 Jun 2017
Structural and mechanistic basis of differentiated
inhibitors of the acute pancreatitis target
kynurenine-3-monooxygenase
Jonathan P. Hutchinson1, Paul Rowland1, Mark R.D. Taylor2, Erica M. Christodoulou1, Carl Haslam1,
Clare I. Hobbs1, Duncan S. Holmes3, Paul Homes1, John Liddle3, Damian J. Mole4,5, Iain Uings3, Ann L. Walker3,
Scott P. Webster6, Christopher G. Mowat2 & Chun-wa Chung1
Kynurenine-3-monooxygenase (KMO) is a key FAD-dependent enzyme of tryptophan
metabolism. In animal models, KMO inhibition has shown benefit in neurodegenerative
diseases such as Huntington’s and Alzheimer’s. Most recently it has been identified as a
target for acute pancreatitis multiple organ dysfunction syndrome (AP-MODS); a devastating
inflammatory condition with a mortality rate in excess of 20%. Here we report and dissect
the molecular mechanism of action of three classes of KMO inhibitors with differentiated
binding modes and kinetics. Two novel inhibitor classes trap the catalytic flavin in a previously
unobserved tilting conformation. This correlates with picomolar affinities, increased residence
times and an absence of the peroxide production seen with previous substrate site inhibitors.
These structural and mechanistic insights culminated in GSK065(C1) and GSK366(C2),
molecules suitable for preclinical evaluation. Moreover, revising the repertoire of flavin
dynamics in this enzyme class offers exciting new opportunities for inhibitor design.
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I
n mammals, tryptophan is an essential amino acid and the major
metabolic route of tryptophan degradation in peripheral tissues is
via the kynurenine pathway1,2. A number of the metabolites of
this pathway have biological activity and imbalances in their levels
have been implicated in neurological disorders such as Alzheimer’s3
and Huntington’s4, as well as inflammatory indications including
multiple sclerosis5 and acute pancreatitis6,7. Kynurenine-3-
monooxygenase (KMO) is a class A flavoprotein monooxygenase
(FPMO) which catalyses the hydroxylation of L-kynurenine (L-Kyn)
to 3-hydroxykynurenine (3-HK), using NADPH as a co-substrate. It
lies at a key branch point of the kynurenine pathway and its
expression is largely restricted to the liver, kidney, some monocytic
cells, and to a lesser extent in the microglia within the brain. 3-HK is
widely described as a neurotoxin that contributes not only to
neurodegenerative disorders, but also oxidative stress, for example,
in the eye during cataract formation, and can induce apoptotic
cell death in endothelial cells8.
The enzymatic mechanism of KMO has been most extensively
characterized using the Pseudomonas fluorescens (Pf) bacterial
system (Fig. 1)9. In the reductive half of the catalytic cycle,
kynurenine and NADPH are bound and flavin reduction occurs by
hydride transfer. Dissociation of the first product (NADPþ )
completes the half-reaction. The rate of flavin reduction is greatly
increased by the presence of kynurenine within the complex,
(by a factor ofB2.5 103 in P. fluorescens), a feature which acts as
a gating mechanism to prevent uncoupled NADPH turnover9.
In the oxidative half reaction, molecular oxygen reacts with the
reduced flavin to form a highly reactive, but weakly electrophilic
C4a-hydroperoxide intermediate, which hydroxylates the activated
aromatic ring of L-Kyn leaving a C4a-hydroxy flavin species.
Elimination of water from this species returns the flavin to the
oxidized state. 3-hydroxykynurenine dissociation completes the
cycle and is believed to be the rate limiting step for Pf-KMO9.
Pharmacological inhibition of KMO has shown promise in
animal models of Alzheimer’s and Huntington’s disease amelior-
ating neurodegeneration, preventing spatial memory deficits,
anxiety-related behaviour and synaptic loss2,3, although this
appears not to be sufficient to alter progression in chronic
disease10. Recently, we demonstrated the beneficial role of KMO
inhibition in the pathogenesis of acute pancreatitis6. This disease
is typically caused by gallstones or excessive alcohol consumption.
For the majority of acute pancreatitis patients, symptoms resolve
within a week or so. However, in approximately one in five cases,
the disease progresses to multiple organ failure with a mortality
rate that exceeds 20% (refs 7,11). Currently no disease modifying
treatments are available and medical care is solely supportive
which indicates a high unmet medical need.
The first discovered KMO inhibitors were analogues of the
substrate L-Kyn which stimulated the production of cytotoxic
hydrogen peroxide by triggering uncoupled NADPH oxidation
within the KMO catalytic cycle9. Here we describe the molecular
mechanism of three novel classes of KMO inhibitors with distinct
binding modes and kinetics. Two of these classes trap the flavin in a
previously unseen ‘tilting’ conformation, which correlates with
picomolar affinities and increased residence times. We term these
type II KMO inhibitors and offer a structural rationale for the
absence of peroxide production despite occupation of the substrate
site. We believe these are the first reported inhibitors that exploit this
flavin motion in class A FPMOs, suggesting targeting flavin dynamics
may be a productive opportunity for novel inhibitor design.
Results
Pf-KMO as a structural surrogate for inhibitor design. KMO
has only 10% sequence identity to the prototypical enzyme in this
class, p-hydroxybenzoate hydroxylase (PHBH) and on initiation
of our studies no structure of KMO had been determined. Human
KMO is a 56 kDa protein containing a tightly bound FAD
cofactor and is attached to the mitochondrial outer membrane via
a C-terminal region. While we were able to produce human
protein suitable for mechanistic studies12, attempts to generate a
human form suitable for crystallography were unsuccessful; the
crystal structure of human KMO is still unknown. We therefore
turned our attention to the homologous bacterial P. fluorescens
enzyme, Pf-KMO, which shares 34% sequence identity with the
human enzyme, but lacks the transmembrane region and had
been previously extensively characterized by Crozier-Reabe et al.9
(Supplementary Fig. 1).
Initial substrate bound Pf-KMO crystals showed poor X-ray
diffraction. Subsequent growth optimization and the generation
of a double C252S/C461S Pf-KMO-mutant enabled us to solve
our first structure using a selenomethionine-labelled protein to a
modest resolution of 3.4 Å (ref. 6). Further rounds of
improvement were successful in delivering a high resolution-
diffracting monoclinic crystal form with two holoenzyme
molecules in the asymmetric unit that was amenable to ligand
soaking studies. This system was adopted to generate the
substrate bound Pf-KMO structure shown in Fig. 2 and for
subsequent inhibitor complexes.
The crystal structure of Pf-KMO in complex with substrate was
determined at 1.5Å resolution (Fig. 2). The KMO monomer
consists of three domains: the aþ b FAD-binding domain, an
aþ b domain containing a six-stranded, mostly antiparallel,
b-sheet and a C-terminal four-helix bundle domain (Fig. 2b).
The active site is predominantly lined by the small hydrophobic
side chains of the six-stranded b-sheet on one side (domain 2) and
on the other by the backbone of the P318-Q322 loop and residues
from the long a-helix (domain 1) which leads to the C-terminal
domain 3 (Fig. 2a,b). Substrate binds in the active site pocket, at the
interface of the first two domains, with the aromatic ring lying
adjacent and perpendicular to the flavin isoalloxazine ring, the
aminobenzaldehyde ring being closest to the FAD, and the
carboxylate chain leads out towards the opening of the active site
entrance channel (Fig. 2b,c). The ring occupies a pocket lined
mostly by hydrophobic residues (F238, P318, F319, H320, G321,
A56, I106, L213 and M373) while the carboxylate and amino
substituents interact with hydrophilic residues; the carboxylate
forms a salt bridge with R84 and the amino group hydrogen bonds
to the sidechain of Y98 (Fig. 2c,d). All the active site residues are
conserved between the P. fluorescens and human enzymes, with the
exception of H320, which is a phenylalanine in the human protein
and a tyrosine in yeast (Fig. 2, Supplementary Fig. 1). This
structural similarity is mirrored by comparable kynurenine Km
values for P. fluorescens and human enzymes (Fig. 2f).
A chloride ion could be modelled into electron density on the
re face of the flavin cofactor (Fig. 2e). Sitting within a curved stretch
of backbone, the halide makes interactions with the amides of G323
and Q322 on one side, the hydrophobic ring of P318 on another
and two waters at 3.0 and 3.2Å complete this coordination. This
constellation of interactions bears a striking resemblance to that
seen for chloride ions in FAD-dependent tryptophan halogenases
such as PrnA13 and RebH14 where the halide acts as a co-substrate
(Supplementary Fig. 2). In flavin hydroxylases such as 3-
hydroxybenzoate 6-hydroxylase15 and KMO the chloride ion
appears to play a more passive role, as a placeholder for the space
predicted to be occupied by the oxygen atoms of the flavin-
hydroperoxide intermediate. In this context, many flavoprotein
hydroxylases, including KMO, are inhibited by chloride ions15,16.
While the structure of human KMO has remained elusive,
that of the yeast orthologue has recently been reported in a holo
and inhibitor (UPF648) bound form; no substrate complex
could be obtained17. Reassuringly the yeast protein has a similar
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architecture to that of our bacterial enzyme, but as a two domain
yeast truncate was crystallized, this lacks insights into the role of
the C-terminal domain 3 present in all three native enzymes and
unique amongst FPMOs (Supplementary Figs 1 and 3). The
Pf-KMO-L-Kyn complex reveals domain 3 further encloses the
substrate channel shielding it from bulk solvent (Supplementary
Fig. 3) and importantly completes the active site architecture
donating residues such as Y404 that directly interact with
L-Kyn (Fig. 2d, Supplementary Fig. 3). Contrary to predictions,
including a KMO-substrate model based on the yeast structure,
the carbonyl of L-Kyn makes no direct interactions with Pf-KMO
and is not a key recognition motif. Many substrate-based
inhibitors have H-bond acceptor motifs assumed to mimic this
carbonyl; in light of this structure any positive contributions
these make may need to be re-interpreted by the presence of
additional interactions or conformational considerations. The
intact Pf-KMO structure therefore provides a more complete
picture of the catalytic site and significantly enhances our ability
to drive structure-based drug design for KMO.
Design of substrate-based inhibitors. Keen to understand the
potential of our Pf-KMO surrogate crystal system to guide
structural insights into the mechanism and inhibitor mode of
action for the human enzyme, we profiled the inhibitor phar-
macology across three distinct series of compounds (Fig. 3a).
Encouragingly, while inhibitors generally appear less potent in
the bacterial enzyme, the rank order of inhibitory activities
was conserved between the two species, suggesting despite the
low-sequence conservation outside the active site, Pf-KMO has
preserved the pharmacology for our inhibitors of interest (Fig. 3b,
Table 1). Consequently Pf-KMO has been used as a structural
substitute for human KMO in our structure-based drug design
efforts, but the human enzyme has been used for all other in vitro
and cellular studies (unless explicitly specified).
A number of KMO inhibitor series have been reported10,18.
The majority share a common pharmacophore containing both
an acidic moiety and a mono or 1,2-dichloro substitution of the
core phenyl ring, including our previously reported oxazolidinone
molecule, GSK180(A1)6. Replacement of one chlorine by methyl
gave GSK428(A2), which showed a more attractive overall
profile19,20. These are all believed to share a common mode of
action, binding within the substrate site and this was confirmed
for GSK428(A2) both enzymatically and by determining X-ray
structures of complexes with Pf-KMO (Fig. 4a–d).
Comparison of the bound structures of L-Kyn and GSK428(A2)
(Fig. 4b) show the aromatic rings of L-Kyn and GSK428(A2) lie in
the same plane. The ring oxygen of the oxazolidinone overlaps with
the carbonyl of L-Kyn and similarly makes no direct interactions,
whereas the carbonyl of the oxazolidinone hydrogen bonds to Y404
and via a bridging water to the backbone carbonyl of G321. The
pendant acid of GSK428(A2) makes slightly different interactions
in Chains A and B. In chain A there are direct interactions with
Y98 and N369 (Fig. 4a), whereas in Chain B these are water-
bridged as seen for the substrate (Figs 2d and 4b).
Enticed by the opportunity to explore a water filled pocket
formed by N54, E195, L226 and T236 off the methyl position of
GSK428(A2) (Fig. 4d), compounds were made with a variety of
substitutions to probe the tolerances within this space19,20.
Unexpectedly, a jump in affinity occurred when alkoxyl-
linked pyridyl groups such as those present in GSK891(B1)
and GSK775(B2) were added. This was puzzling as although
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Figure 1 | Catalytic cycle of KMO. Schematic of the sequence of catalytic steps involved in the hydroxylation of L-Kyn to 3-HK by the FAD-dependent KMO
enzyme9. For clarity, chemical structures are drawn only for the isoalloxazine ring of the catalytic flavin and the L-Kyn substrate.
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modelling using Pf-KMO had suggested there was sufficient room
to accommodate the pendant pyridine, there were no predicted
interactions to explain the observed potency increase (Fig. 4e).
Our best hypothesis was a possible edge to face interaction with
the flavin ring that limits one side of the pocket (Fig. 4f).
Intriguingly, initial enzymatic mode of action analysis of series B
compounds, such as GSK775(B2), under the same conditions as
used for GSK428(A2) suggested non-competitive behaviour
(Fig. 4c), leading us to question our assumptions about the
binding site and mode of action for these compounds.
Novel inhibitors have a distinct-binding mode and kinetics.
A structure of GSK775(B2) in Pf-KMO confirmed that it binds
within the substrate site (Fig. 5a), with the oxazolidinone core
overlapping almost exactly with that in series A compounds.
However, the pendant pyridyl group does not reside in the water
filled pocket as modelled in Fig. 4e,f. Instead, it p-stacks against a
flavin group that is now tilted away from the substrate site in an
orientation not previously observed in KMO, or any other FPMOs
we have found (Fig. 5a). In addition to the face to face p interaction
with FAD the pyridine also makes edge to face p interactions with
Y193 and F238 (Fig. 5b). Flavin movement creates a new solvent
channel that opens the active site to the protein surface (Fig. 5c),
the pyridine nitrogen of GSK775(B2) H-bonds with an extended
water network within this opening (Fig. 5c). R111 needs to move in
concert with this flavin tilt, but few other protein changes are
necessary to accommodate this movement.
Since GSK428(A2) and GSK775(B2) both occupy the L-Kyn
site, the non-competitive behaviour we observed for GSK775(B2)
was perplexing, prompting us to undertake a more detailed
characterization of the binding kinetics of these compounds
(Fig. 5d,e).
First, we characterized the association kinetics by monitoring
the onset of inhibition timecourses. For GSK428(A2) timecourses
in the presence of inhibitor were linear in the shortest timescale
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Figure 2 | Pf-KMO as a structural surrogate for human inhibitor design. (a) Domain structure of Pf-KMO mapped onto a schematic of the primary
sequence of the construct crystallized. Domain 1 (blue) is the FAD-binding domain; domain 2 (purple) is a second domain conserved in FPMO enzymes;
domain 3 (orange) is a domain unique to KMO. Protein residues retain this domain colouring throughout this figure. (b) 1.5Å X-ray crystal structure of Pf-
KMO complexed with substrate, L-Kyn (space fill, carbons in green), FAD (space fill, carbons in yellow). Protein shown in cartoon format. (c) Binding of
L-Kyn within KMO active site. (d) Alternative view of L-Kyn within KMO active site overlaid with Saccharomyces cerevisiae KMO-UPF648 inhibitor complex
(white carbons, PDB 4J36)17. (e) Chloride ion (green sphere) bound beneath flavin Pf-KMO, as seen for other family members (Supplementary Fig. 2).
(f) Determination of L-Kyn KM values for Pf-KMO and human KMO proteins using a Rapidfire mass spectrometry assay
12. L-Kyn KM values of 7 mM for Pf
KMO and 2 mM for human KMO were measured in the presence of 200mM NADPH, with corresponding kcat values of 2.3 and 0.24 s 1.
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that could be achieved in manual mixing experiments, indicative
of rapid association on this timescale with kobs greater than
0.6min 1 under these conditions (Supplementary Fig. 4a).
However for GSK775(B2), under the same concentration
conditions, clear curvature in the presence of inhibitor was seen
indicative of slow onset of inhibition (Fig. 5d). Exponential
analysis gave a kobs value of 0.062min 1, at least 10 times slower
than for GSK428(A2). Dissociation kinetics were characterized by
pre-equilibrating enzyme with an excess of inhibitor, and
initiating reactions by adding a large excess of L-Kyn relative to
KM to drive maximum recovery of activity. Figure 5e shows the
timecourse of recovery of activity after adding substrate. For
GSK428(A2) no evidence of a lag in recovery of enzyme activity
was seen in the shortest timescale that could be achieved in
manual mixing experiments, indicative of rapid dissociation on
this timescale, with kobs greater than 1.0min 1 (Supplementary
Fig. 4b). For GSK775(B2) a lag phase was clearly observed
indicative of slow dissociation on this experimental timescale,
with kobs¼ 0.006min 1.
Taken together these data suggest a differentiated kinetic
profile for GSK775(B2) and GSK428(A2), with GSK775(B2)
showing slow onset of inhibition and slow dissociation, in
contrast to the rapid kinetics of GSK428(A2). The apparently
non-competitive behaviour of GSK775(B2) can be rationalized
by the unexpected slow dissociation of the prebound inhibitor
relative to the timescale of the initial competition assay
(B2 h half life for the KMO-GSK775(B2) complex).
Tilting inhibitors designed for potency and residence times. To
further improve the pharmaceutical properties of our inhibitors
and to investigate whether inducing a tilting flavin could be a
general tactic used to deliver high potency and long residence
times for this important enzyme, we used the KMO-GSK775(B2)
crystal structure to design molecules that differed in both the
heterocyclic core and the tilt inducing pendant group20.
Grafting the 1-(pyridin-2-ylethoxy) pendant group of
GSK775(B2) onto the benzisoxazole core gave GSK065(C1)
which preserves the tilting flavin and maintains the high
in vitro activity of GSK775(B2) (IC50¼ 2.5 nM, n¼ 12). A variety
of alternative ‘tilting’ pendant substituents were also incorporated
onto the benzisoxazole ring, as exemplified by the methyl-
pyridazine ring of GSK366(C2). This aromatic ring retains the
tilting flavin conformation (Fig. 6a), as expected, and induces an
even clearer network of water interactions within the new solvent
channel (Fig. 6b). Pyridazine has been promoted as an excellent
bioisostere for pyridine, often with the ability to enhance
solubility and decrease metabolic liability21. The mean
potencies of GSK366(C2) and GSK065(C1), 2 nM (n¼ 4) and
4.5 nM (n¼ 7) respectively, are of the same order as the
concentration of human enzyme added to the reaction and the
slopes of their inhibition curves are steep for both compounds;
both have a mean slope of 1.9. This suggests the IC50 values
quoted may underestimate their true affinities. Indeed, detailed
kinetic analysis for GSK065(C1) and GSK366(C2) (Fig. 6c,d,
Supplementary Figs 5 and 6) suggest that their true Kis may be
around 50 pM and 12 pM, respectively. The slow onset of
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Table 1 | IC50 values obtained from the inhibition curves
shown in Fig. 3b.
Compound IC50 Human KMO IC50 Pf-KMO
GSK366 2.3 nM 0.7 nM
GSK775 2.7 nM 3.0 nM
GSK891 3.6 nM 4.3 nM
GSK428 10.0 nM 60.0 nM
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inhibition and slow dissociation from the KMO enzyme for series
C compounds are readily apparent, with GSK366(C2) exhibiting a
dissociation half life of the order of 12 h (Fig. 6d).
The benzisoxazole series, exemplified here by GSK065(C1) and
GSK366(C2), illustrates the ability to translate our original
observation of tilting flavin and slow kinetics to successfully
design new inhibitors that preserve this unusual-binding mode
and desirable kinetic signature22–24.
Type II inhibition does not stimulate peroxide generation.
Flavin dynamics during the catalytic cycle of FPMO class A
enzymes has been a subject of considerable interest, as orche-
strated motions potentially govern substrate binding and product
release as well as being critical for regulation of the reductive
and oxidative steps of the catalytic process. A range of flavin
conformations has been captured by structural studies, leading to
terms such as ‘waving’25–27 and ‘flapping’28 flavin to describe the
repertoire of motions observed. The tilting flavin orientation seen
for series B and C inhibitors does not match any of those reported
and is much more appropriately described as a tilt, as it lacks the
lateral motion for the wave that leads to the ‘out’ state first
reported in the class A exemplar enzyme PHBH (Fig. 7a).
In PHBH, flavin movement from the in to the out state is
governed by the protonation state of the phenolic substrate, with
only the out flavin believed to be accessible for hydride transfer
from a transiently bound NADPH molecule29. Once reduced, the
flavin swings back into the enclosed active site and sits in the
in conformation ready for incorporation of molecular oxygen to
form the reactive C4a-hydroperoxide intermediate, which then
hydroxylates the prebound substrate. This acts as a control point
to ensure efficient coupling of reductive and oxidative steps in the
catalytic cycle, with the hydroperoxy flavin only produced when
the substrate is present to accept its hydroxy modification.
Dissociation of substrate before hydroxylation results in the
uncoupled production of hydrogen peroxide. Unactivated
substrate mimetics such as NBA and BA are KMO inhibitors
known to stimulate peroxide (H2O2) production as the catalytic
cycle is frustrated at the hydroxylation step and the system cycles
by eliminating hydrogen peroxide9 and we also observe similar
behaviour with GSK428(A2) using an HRP/Amplex Red assay to
detect peroxide formation (Fig. 8). However, inhibitors from
series B and C did not stimulate H2O2 production, and in
the human enzyme there was even an apparent reduction of
H2O2 production below basal levels (Fig. 8a). Given this
distinctive mechanism and binding mode we decided to name
this mechanism of inhibition type II, to distinguish it from
the simple substrate mimicry that stimulates H2O2 production
(type I inhibitor).
We hypothesized that the unique tilting flavin conformation
induced by our series B and C inhibitors may interrupt the
catalytic cycle of KMO at an alternative junction to simple
substrate mimetics, trapping the isoalloxazine ring in a limbo
state unable to the complete the trajectory required to be reduced
by NADPH or form the hydroperoxo species. Curious to provide
greater mechanistic rationale for this distinction we attempted to
co-crystallize substrate and inhibitors in the presence of NADPH
as well as with a small nicotinamide molecule, all without success.
While it is assumed that simultaneous binding of FAD-NADPH-
substrate is a requisite for ‘cautious’, class A, FPMO regulation30,
ternary X-ray complexes are scarce. The only known NADPH
bound complex of a class A enzyme, is that of a PHBH Variant,
R220Q (PDB ID:1KOJ26). Surprisingly this captures the NADPH
within a surface groove in an extended conformation where the
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variations of interactions, between the two chains are apparent, for example, monodentate salt bridge with R84. To illustrate relative position of native
substrate, Pf-KMO-L-Kyn complex structure is shown in yellow (c) Effect of [L-Kyn] on IC50 of GSK428(A2) and GSK775(B2) for human KMO. A linear
relationship, as seen for GSK428(A2), is typical of simple Kyn-competitive inhibitors. The behaviour of GSK775(B2), which shows no dependence on
[L-Kyn], is expected of non-competitive inhibitors. (d) Active site with GSK428(A2) bound (chain A) and surface representation (grey) of protein to
highlight water filled pocket used for inhibitor design (e,f) Modelled structure of GSK775(B2) (pink) preserving the position of the oxazolidinone core and
placing the pendant pyridine into this cavity, overlaid with GSK428(A2) structure. The close proximity of the pyridine to the flavin is apparent.
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nicotinamide extends away from, rather than towards active site31
suggesting this may be an unproductive-binding mode.
Mutagenesis studies do suggest residues that line this surface
channel (R33, Y38, Y42, Y44, F161, R166) are involved in
NADPH binding, but spectroscopic data are more consistent
with a reverse orientation that more simply brings the
nicotinamide ring close to the flavin in its out conformation.
Many of these residues lie within the solvent channel identified as
accessible from the active site in our tilting flavin structures,
enabling us to model a NADPH molecule along this channel to
place the nicotinamide ring on the re face of the flavin.
Interestingly, this ring position closely resembles that found in
the catalytically competent FAD-NADPH-substrate complexes of
class B monoxygenases28,32,33 (Fig. 7c,d, Supplementary Fig. 7).
Trapping class B, ‘bold’, monooxygenases, during the catalytic
cycle has been more successful. In these sister enzymes reduction
of FAD by NADPH occurs equally well in the presence or
absence of bound substrate. To protect against uncoupling of the
reductive and oxidative half cycles, the spent NADP(H) cofactor
remains bound to the protein throughout the reaction cycle,
protecting both the reduced and the C4a-hydroperoxide species
from being quenched30. Dramatic changes in the flavin include a
flipped orientation (Fig. 7c) observed along a catalytic trajectory
captured in a remarkable series of crystal structures of the class B
hydroxylase, KtzI28, that traps reduced, oxidized and various
substrate and cofactor bound states. Transition between the
in and a flipped flavin orientation requires a 180 rotation of the
isoalloxazine ring, leading to the idea that a ‘flapping’ flavin
motion may be required for this enzyme28. Importantly, these
snapshots include those in the presence of NADP(H) providing
an invaluable window into the choreographed motions of flavin
and nicotinamide rings within the reaction cycle.
Our modelled ternary KMO complex suggests the degree of
flavin motion could also be subtlely divergent amongst class A
enzymes, with a tilting flavin creating sufficient space to
accommodate NADPH binding (Fig. 7d). This close arrangement
of NADPH, FAD and substrate may account for the relatively
low KM measured for NADPH for human KMO12. The model
suggests the nicotinamide ring could get close enough to occupy
the same space as the pendant group of our type II inhibitors. The
observed rate of inhibitor binding is not diminished in response
to increasing NADPH concentrations (Supplementary Fig. 9),
which suggests that the inhibitor and NADPH bind to different
states of the enzyme, but this does not exclude the possibility that
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Figure 5 | Differential structural and kinetic signatures of series A and B. (a) Crystal structure of GSK775(B2) bound in Pf-KMO (magenta) overlaid with
that of GSK428(A2) (cyan). Tilting movement of the flavin, away from pyridine group shown by arrow. H-bonds of oxazolidinone core are maintained by
both inhibitors (red). (b) Environment around GSK775(B2) pyridine. H-bonding with water network now accessible due to flavin movement, p-stacking
interactions with flavin. (c) Movement of flavin creates a solvent filled channel from active site to surface of the protein. (d) Onset of inhibition for
GSK428(A2) and GSK775(B2) for human KMO. Uninhibited timecourse (open symbols), onset of inhibition timecourse in the presence of 10 nM inhibitor
(closed symbols). No evidence of slow binding was seen for GSK428(A2) on this timescale. GSK775(B2) showed slow onset of inhibition with
kobs¼0.062min 1. (e) Recovery of activity for GSK428(A2) and GSK775(B2) for human KMO. Uninhibited timecourse (open symbols), recovery of
activity timecourses (closed symbols). No evidence of slow recovery of activity was seen for GSK428(A2) on this timescale. GSK775(B2) showed slow
recovery of activity with kobs¼0.006min 1.
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type II inhibitors may change the ability of NADPH to bind to
the inhibited enzyme, or do so in a productive manner. For
example, they may inhibit the reductive step consistent with the
tilting flavin being a high energy conformation induced only by
type II inhibitor binding, or perhaps a transient state along the
catalytic trajectory pinned by the inhibitor in a conformation that
is unable to be reduced by NADPH binding or oxidized by
molecular oxygen (Fig. 8b).
In summary, type II inhibitors may exert three concerted but
separate effects: first, prevent productive association with
NADPH, killing the reductive half-reaction; second, prevent
substrate binding, killing the oxidative half-reaction; and finally,
pushing the FAD into an unproductive position. The balance of
these contributions may vary amongst inhibitors. Therefore, type
II KMO inhibitors realize the ideal profile of preventing 3-HK
generation without peroxide generation and provide a structural
template of how this can be achieved. This represents a major step
in drug design for KMO.
Discussion
KMO is an important metabolic enzyme and drug target for
which structural insights have so far been remarkably limited.
While the human enzyme has been recalcitrant to structural
studies a double mutant of Pf-KMO has enabled the first
substrate bound structure to be determined. Success was made
possible by the use of a full-length P. fluorescens orthologue that
included not only the FAD and substrate-binding domains
common to all FPMOs but also a third C-terminal domain that is
unique to the KMO enzyme. This inclusion proved critical to full
understanding of substrate site recognition, as the novel helical
domain is an integral part of the substrate-binding site. The
KMO-L-Kyn complex brings new insights into substrate binding
and challenges dogma in the design of KMO inhibitors. For
example, it has long been assumed essential to include a hydrogen
bond acceptor to mimic key interactions made by the carbonyl of
L-Kyn, yet in our structure the carbonyl makes no significant
interactions. This crystallographic system therefore represents a
significant advance in our ability to apply structure-based design
to inhibitors of this enzyme, allowing us to address puzzling
structure–activity relationships and providing a firm basis for
novel inhibitor discovery and mechanistic analysis.
This promise has already been realized with our discovery of
the first type II KMO inhibitors that bind to an unprecedented
tilting flavin conformation. Crystallographic complexes of our
extended oxazolidinone inhibitor series (B) rationalize their
unexpectedly high potency, by demonstrating that they bind with
this intriguing variation of the flavin position. Unlike previous
substrate site inhibitors that carry the mechanistic liability of
stimulated hydrogen peroxide production, type II compounds
prevent formation of the flavin peroxo species and do not possess
this undesirable side effect. Trapping the flavin in an unproduc-
tive orientation decouples substrate site binding from NAPDH
reduction and flavin oxidation and is associated with increased
inhibitor residence times. These type II inhibitors therefore have
all the hallmarks of ideal KMO inhibitors. Our understanding of
their structural and mechanistic basis has enabled us to translate
these ideal attributes to distinct chemical series as exemplified by
the optimized type II benzisoxazole compounds GSK065(C1)
and GSK366(C2). These have the full profile of pharmaceutical
and pharmacological in vitro and in vivo properties that make
them suitable candidates for progression to clinical evaluation in
acute pancreatitis multiple organ dysfunction syndrome20.
Many FAD-dependent monooxygenases depend on carefully
choreographed flavin motions for catalysis. While we are the
first to report type II inhibitors for FPMOs, trapping the flavin in
unproductive positions may be a general approach applicable to a
broad range of FPMOs, opening the doors to rich opportunities
for innovative inhibitor design.
Methods
Protein expression and purification. For the structural studies of apo and
inhibitor-bound Pf-KMO, the expression vector pET17b Pf-KMO C252S/C461S34
was transformed into Escherichia coli BL21 (DE3). Cells were plated onto LB agar
plates containing 100mgml 1 ampicillin and incubated for 16 h at 37 C. Plates
were scraped into 200ml LB broth and used for the inoculation of 12 1 l of LB
broth. The culture was grown for 12–16 h (until OD600 2.7) at 22 C. After the agar
plate stage no ampicillin was used, and no IPTG was used for induction. Cells were
collected by centrifugation, chilled to 4 C and frozen at  80 C.
Cells were resuspended in 20mM Hepes pH 7.5 containing 1mM DTT, 100 mM
FAD and protease inhibitor cocktail (100 mM AEBSF, 80 nM aprotinin, 5 mM
bestatin, 1.5 mM E-64, 2 mM leupeptin, 1 mM pepstatin A). The cell suspension was
lysed by sonication with ice cooling. The suspension was centrifuged at 30,750g for
30min at 4 C. Streptomycin sulfate was added to the supernatant over 15min to a
final concentration of 1.5% w/v. The suspension was centrifuged at 19,700g for
10min. The supernatant was slowly brought to 50% ammonium sulfate saturation
over 20min at 4 C. The suspension was centrifuged at 19,700g for 10min. The
pellet was dissolved in 20mM Hepes pH 7.5, 1mM DTT and the solution was
frozen at  80 C before being further purified.
A 15Q Source ion exchange column was equilibrated with 20mM Hepes
pH 7.5, 10mM NaCl, 1mM DTT at 5mlmin 1. The redissolved ammonium
sulfate pellet from above was loaded to the column at 4mlmin 1 followed by
extensive washing with buffer at 5mlmin 1. The column was eluted at
5mlmin 1 with a 20min gradient to 20mM Hepes pH 7.5, 500mM NaCl, 1mM
DTT. The Pf-KMO containing peak was further purified by size exclusion
chromatography on a HiLoad 26/60 Superdex 200 column equilibrated in 20mM
Hepes pH 7.5, 10mM NaCl, 1mM DTT run at 1mlmin 1. Fractions containing
pure Pf-KMO were pooled, supplemented with 5% glycerol, concentrated to
18mgml 1 using an Amicon 10,000 molecular weight cut-off centrifugal
concentrator and frozen at  80 C in aliquots.
For the expression and isolation of human KMO membranes, full-length
human KMO was cloned as an N-terminal GST fusion, expressed in Sf9 cells and
isolated as a membrane fraction as described in Lowe et al.12
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Figure 6 | The benzisoxazole inhibitor series maintain the tilting flavin
orientation that retains slow kinetics. Panels a–d show the characterization
of the representative series C inhibitor, GSK366(C2). (a,b) GSK366(C2) binds
in the active site and tilts the flavin to access and make even more extensive
interactions with the new water filled channel. (c) Onset of inhibition for
GSK366(C2) for human KMO. Uninhibited timecourse (open symbols), onset
of inhibition timecourse in the presence of 5 nM GSK366(C2) (closed
symbols). Slow onset of inhibition was observed with kobs¼0.031min 1.
(d) Recovery of activity timecourse for GSK366(C2). Uninhibited timecourse
(open symbols), recovery of activity timecourse (closed symbols). Slow
recovery of activity was observed with kobs¼0.001min 1.
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For the structural studies of the L-Kyn Pf-KMO complex, the expression vector
pET17b Pf-KMO C252S/C461S34 was transformed into E. coli BL21 (DE3). Cells
were added to 10 10ml LB broth containing 100 mgml 1 ampicillin and
incubated for 16 h at 37 C with shaking at 200 r.p.m. The 10ml starter growths
were added to 10 1 l of LB broth containing 25 mgml 1 ampicillin. The culture
was grown for 12–16 h at 37 C with shaking at 180 r.p.m., no IPTG was used
for induction. Cells were collected by centrifugation, chilled to 4 C and frozen
at  20 C.
Cells were resuspended in 20mM Hepes pH 7.5 containing 10mM NaCl, 1mM
DTT and 200 mM PMSF. The cell suspension was lysed by sonication with ice
cooling. The suspension was centrifuged at 47,800g for 60min at 4 C. The
supernatant was filtered through a 0.45 mm MF-Millipore membrane and loaded
onto a 60ml FPLC Q Sepharose 26/10 column pre-equilibrated with 20mM Hepes
pH 7.5, 10mM NaCl, 1mM DTT at 4mlmin 1. The column was then washed
with 400ml 20mM Hepes pH 7.5, 50mM NaCl, 1mM DTT at 4mlmin 1.
The column was eluted with 500ml 20mM Hepes pH 7.5, 110mM NaCl,
1mM DTT at 4mlmin 1. The pooled fractions of Pf-KMO was slowly brought
to 50% ammonium sulfate saturation over 20min on ice. The suspension was
centrifuged at 38,720g for 20min at 4 C. The pellet was frozen at  20 C before
being further purified.
The ammonium sulfate pellet was dissolved in 20mM Hepes pH 6.8 containing
10mM NaCl and 1mM DTT. This solution was concentrated by centrifugation
using VIVASPIN MW 30,000 concentrators to a volume of 2ml. This was loaded
onto a 320ml 26/600 Superdex 75 column equilibrated with 20mM Hepes pH 6.8,
10mM NaCl, 1mM DTT and run at 1mlmin 1. Fractions containing pure
Pf-KMO were pooled, supplemented with 5% glycerol, and concentrated by
centrifugation using VIVASPIN MW 30,000 concentrators to 32mgml 1.
Aliquots were flash frozen in liquid nitrogen and stored at  80 C.
Crystallization and structure determination. To determine the structure of
apo and inhibitor-bound KMO, crystals of P. fluorescens KMO were grown at 4 C
by sitting drop vapour diffusion using a protein concentration of 18mgml 1,
with crystallization solutions consisting of either 20% glycerol, 14.4% PEG 8000,
0.08M sodium cacodylate pH 6.5, 0.16M calcium acetate or 20% glycerol,
16% PEG 8000, 0.08M sodium cacodylate pH 6.5, 0.16M magnesium acetate.
Crystallization drops were set-up using 100 nl protein solution mixed with 100 nl
crystallization solution (or 200 nlþ 200 nl) above a reservoir of 40 ml of the same
crystallization solution.
To make the crystal soaking solutions 1 ml of a 500mM compound stock
solution in DMSO was added to 19 ml of the crystallization solution to give a
compound concentration of B25mM (5% DMSO). The crystal soaking solution
was added to the crystallization drop to excess and left at 4 C for 3–8 h. Crystals
were then frozen in liquid nitrogen directly from the soaking drops, without any
additional cryo-protectant.
X-ray diffraction data were collected at 100K at the European Synchrotron
Radiation Facility (ESRF). The data were processed and scaled using autoPROC35
or the ESRF automated beam line data processing software, utilizing XDS36,
AIMLESS37 and the CCP4 suite of programs38. The crystal space group is P21 with
unit cell dimensions approximately a¼ 69.7 Å, b¼ 53.1 Å, c¼ 136.5Å, a¼ 90,
b¼ 103.8, g¼ 90 and two protein molecules in the asymmetric unit. Data
collection statistics (Supplementary Table 1).
The structures were determined using the coordinates of an isomorphous
unliganded protein model, with preliminary refinement carried out using
autoBUSTER39. In all cases, the ligands were clearly visible in the resulting Fo Fc
electron density maps (Supplementary Fig. 8). Coot40 was used for model building,
with refinement completed using autoBUSTER. The statistics for the final models
are given in Supplementary Table 1. The coordinates and structure factors have
been deposited in the Protein Data Bank.
For the structural determination of L-Kyn substrate complex, crystals of
P. fluorescens KMO were grown at 18 C by hanging drop vapour diffusion using a
protein concentration of 32mgml 1, with crystallization solutions consisting of
20% glycerol, a range of 11–19% PEG 8000, 0.08M sodium cacodylate pH ranging
from 5.5 to 7.0 and 0.16M calcium acetate. Crystallization drops were set-up using
2 ml protein solution mixed with 2 ml crystallization solution above a reservoir of
500 ml of the same crystallization solution.
Crystal soaking solution contained 20% glycerol, 25% PEG 8000, 0.08M sodium
cacodylate of pH relevant to the crystallization solution, 0.16M calcium acetate and
1mM L-Kyn. Crystals were extracted from the crystallization solution and placed in a
1ml drop of crystal soaking solution. The well was re-sealed and left for roughly 48 h.
Crystals were then frozen in liquid nitrogen, without any additional cryo-protectant.
X-ray diffraction data were collected at 100 K at the Diamond Light Source. The
data were processed and scaled using iMosflm41 the CCP4 suite of programs38. The
crystal space group is P21 with unit cell dimensions approximately a¼ 69.9 Å,
b¼ 52.6 Å, c¼ 138.0 Å, a¼ 90, b¼ 104.0, g¼ 90 and two protein molecules in
the asymmetric unit. Data collection statistics (Supplementary Table 1).
The structures were determined using the coordinates of an isomorphous
unliganded protein model, with preliminary refinement carried out using Refmac5
IN
OUT
Waving
IN
TILTED
Tilting Flapping
NADPH
(modelled)
a b c
d e
Figure 7 | Repertoire of flavin motion and modelling NADPH binding. (a) Overlay of two PHBH enzyme complexes that depict in (pink, PDB 1DOC)
and out (brown, PDB 1DOD) positions characteristic of ‘Waving’ flavin movement27 that pivots around the ribityl C(2) carbon. (b) Overlay of two
Pf-KMO inhibitor structures that illustrate in (cyan, GSK428(A2)) and tilted flavin positions which hinges on the two carbonyls of the pyrimidinone flavin
ring. (c) Overlay of two class B KtzI N-hydroxylase complexes showing in (white, KtzI FADredNADPþ  L-Orn, PDB 4TLX) and ‘flapped’
(grey, KtzI FADred-oxNADPþ  L-Orn, PDB 4TM0) positions. Reorientation of isoalloxazine ring between two positions has been described as
‘flapping’ as this requires a 180 degree rotation. (d) NADPH molecule is positioned into the solvent channel and active site of the KMO-FAD-GSK775(B2)
complex with the tilting flavin. The GSK775(B2) molecule has been removed and instead L-Kyn is positioned within the active site, guided by the
KMO-FAD-L-Kyn complex. NADPH is positioned to ensure there are no severe atom clashes and maintain an appropriate geometry. No attempts were
made to allow protein sidechain movement or optimize interactions. (e) Same model as (d) with GSK775(B2) rather than L-Kyn preserved in the active site.
The nicotinamide ring of NADPH occurs in the same space as the GSK775(B2) pyridine.
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(ref. 42). In all cases, the ligands were clearly visible in the resulting Fo Fc electron
density maps (Supplementary Figure). Coot40 was used for model building, with
refinement completed using Refmac5. The statistics for the final models are given
in Supplementary Table 1. The coordinates and structure factors will be deposited
in the Protein Data Bank on acceptance of this article.
Enzymatic activity assays and inhibitor-binding kinetics. Inhibitor IC50 values
against isolated human KMO were determined using a Rapidfire mass spectro-
metry assay as described in Lowe et al.12 utilizing the Sf9 cell expressed human
KMO described above. The inhibitor IC50 values against Pf-KMO were determined
using an analogous Rapidfire mass spectrometry assay, utilizing the purified
protein described above. Final assay concentrations were [Pf-KMO]¼ 1 nM,
[L-Kyn]¼ 10mM and [NADPH]¼ 200 mM.
The KM of kynurenine for human KMO and for Pf KMO were measured as
described in Lowe et al.12. The KM of NADPH for human KMO was measured
using a regeneration system as described in Lowe et al.12, with a kynurenine
concentration of 10mM.
For the association kinetics assays, measurements were performed in a buffer of
50mM Hepes pH 7.5, 2mM DTT, 1mM EDTA, 0.1mM Chaps. Reactions were
performed at ambient temperature, by addition of human KMO enzyme to a
mixture of L-Kyn and NADPH containing the test inhibitor. Concentrations of
components after initiation were 8 mgml 1 KMO membranes (B2 nM active
concentration by active site titration), 200 mM NADPH, 10mM L-Kyn and the
stated concentration of inhibitor. Aliquots of the mixtures were quenched into
0.5% TFA in water. L-Kyn and 3-HK levels in the quenched samples were
measured using the Rapidfire mass spectrometry method described in Lowe et al.12
Calibration curves for L-Kyn and 3-HK were used to correct for the lower detection
response for 3-HK. Per cent turnover and resulting concentration of 3-HK were
calculated for each time point in Excel. kobs values for onset of inhibition were
obtained by fitting individual timecourses to equation 1 where t¼ time,
vs¼ steady-state rate, vi¼ initial rate and c¼ background43. vi was fixed at the
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Figure 8 | Type II inhibitors do not promote peroxide generation. (a) Generation of hydrogen peroxide by Pf-KMO and human KMO in the presence of
different inhibitors was monitored in a HRP/Amplex Red assay. Classical (NBA¼m-nitrobenzoylalanine; BA¼ benzoylalanine) and series A compounds
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15827
10 NATURE COMMUNICATIONS | 8:15827 | DOI: 10.1038/ncomms15827 | www.nature.com/naturecommunications
uninhibited rate obtained from the slope of the timecourse in the absence of
inhibitor.
3HK½  ¼ vstþ vi  vskobs 1 e
 kobst þ c ð1Þ
For the full kinetic analysis of GSK065(C1) and GSK366(C2), association
timecourses were measured at multiple inhibitor concentrations and the
association rate constant (kon) was obtained from the gradient of a plot of kobs
against [inhibitor].
For the Association kinetics experiments of GSK775(B2) at sub-saturating
NADPH concentrations, measurements were performed as described above, in the
presence of an NADPH regeneration system comprising D-glucose-6-phosphate
and glucose-6-phosphate dehydrogenase. Concentrations of components after
initiation were 10 nM GSK775(B2), 32 mgml 1 KMO membranes (B8 nM active
concentration by active site titration), 10 mM L-Kyn, 3mM D-glucose-6-phosphate,
1 unit ml 1 glucose-6-phosphate dehydrogenase and the stated concentration of
NADPH. kobs values for onset of inhibition were obtained by fitting individual
timecourses to Equation (2), describing onset of inhibition under non pseudo-first
order conditions43.
The dissociation kinetics measurements were performed in a buffer of 50mM
Hepes pH 7.5, 2mM DTT, 1mM EDTA, 0.1mM Chaps. Mixtures of human KMO
enzyme and excess inhibitor were pre-equilibrated for 1 h at ambient temperature,
after which reactions were initiated by the addition of a high concentration of
L-Kyn. Concentrations of components after initiation were 8 mgml 1 KMO
membranes, 200 mM NADPH, 500 mM L-Kyn and the stated concentration of
inhibitor. Aliquots of the reaction mixtures were quenched into 0.5% TFA in water.
3-HK levels in the quenched samples were measured using the Rapidfire mass
spectrometry assay described in Lowe et al.12 A calibration curve for 3-HK was
used to convert the data to concentration of 3-HK at each time point. kobs values
for recovery of activity were obtained by fitting individual timecourses to
equation 1 with vi (initial rate) set to zero.
For the full kinetic analysis of GSK065(C1) and GSK366(C2), timecourses in the
presence and absence of inhibitor were simultaneously fitted to a kinetic scheme of
competitive inhibition using Kintek v 5.2.16 (refs 44,45). The scheme assumed
rapid equilibrium substrate binding with L-Kyn KD¼KM and an irreversible
hydroxylation step9. In this analysis, inhibitor kon was fixed at the value obtained in
the association kinetic studies, and kcat and inhibitor koff were the two variable
parameters.
Measurement of hydrogen peroxide formation. Measurements were performed
in a buffer of 50mM Hepes pH 7.5, 0.1mM Chaps. A two-fold dilution series of
test inhibitor and control compounds was prepared from DMSO solutions using
the Hewlett-Packard D300 digital dispenser in a 384-well plate and normalized to a
final DMSO concentration of 1% in the assay. 10 ml of 80mgml 1 human KMO or
40 nM Pf-KMO were added. After 15min incubation, 10 ml of a substrate/detection
mix (2Uml 1 HRP, 20 mM Amplex Red, 40mM NADPH) were added and the
plate was read kinetically on a Tecan M1000 fluorescent plate reader with exci-
tation wavelength 530 nm and emission wavelength 580 nm. A calibration curve
comprising a two-fold dilution series of resorufin from 20 mM top concentration
was included on the plate, and used to convert assay data to concentration of
resorufin formed. Initial rate (mMmin 1) was extracted by linear fitting of the
early region of each timecourse. Dose responses were fitted to a four parameter
logistic expression where appropriate.
Data availability. Data supporting the findings of this study are available within
the article and its Supplementary Information files and from the corresponding
author upon reasonable request. The final models of the crystal structures
presented within this paper have been deposited within the protein data bank with
accession codes: 5NA5, 5NAB, 5NAE, 5NAG, 5NAH, 5NAK.
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